Your browser doesn't support javascript.
loading
The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.
Arnaiz, J A; Rodrigues-Silva, C; Mezquida, G; Amoretti, S; Cuesta, M J; Fraguas, D; Lobo, A; González-Pinto, A; Díaz-Caneja, M C; Corripio, I; Vieta, E; Baeza, I; Mané, A; García-Rizo, C; Bioque, M; Saiz, J; Bernardo, M; Mas, S.
Affiliation
  • Arnaiz JA; Phase I Unit, Clinical Pharmacology Department, Hospital Clinic de Barcelona (HCB), Barcelona, Spain.
  • Rodrigues-Silva C; Department of Basic Clinical Practice, University of Barcelona (UB), Casanova 143, E-08036, Barcelona, Spain.
  • Mezquida G; Department of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
  • Amoretti S; Department of Basic Clinical Practice, University of Barcelona (UB), Casanova 143, E-08036, Barcelona, Spain.
  • Cuesta MJ; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, HCB, Barcelona, Catalunya, Spain.
  • Fraguas D; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
  • Lobo A; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.
  • González-Pinto A; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, HCB, Barcelona, Catalunya, Spain.
  • Díaz-Caneja MC; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
  • Corripio I; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.
  • Vieta E; Departmentof Psychiatry, Complejo Hospitalario de Navarra, Instituto de Investigaciones Sanitarias de Navarra (IdiSNa), Pamplona, Spain.
  • Baeza I; Institute of Psychiatry and Mental Health, Hospital Clínico San Carlos, IdISSC, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain.
  • Mané A; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
  • García-Rizo C; Department of Medicine and Psychiatry, Zaragoza University, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain.
  • Bioque M; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
  • Saiz J; Hospital Universitario Araba, Servicio de Psiquiatria, UPV/EHU, Bioaraba, Spain.
  • Bernardo M; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, CIBERSAM, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.
  • Mas S; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Psychopharmacology (Berl) ; 238(3): 665-676, 2021 Mar.
Article in En | MEDLINE | ID: mdl-33230696
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psychotic Disorders / Antipsychotic Agents / Drug Monitoring / Olanzapine Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Psychopharmacology (Berl) Year: 2021 Document type: Article Affiliation country: España
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psychotic Disorders / Antipsychotic Agents / Drug Monitoring / Olanzapine Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Psychopharmacology (Berl) Year: 2021 Document type: Article Affiliation country: España